Accessible Search Form           Advanced Search

9. Research Grants


NHLBI Research Grants by Funding Mechanism: Fiscal Year 2005

  Number of Grants Total Cost (Dollars in Thousands) Percent of Total NHLBI Research Grant Dollars
Research Project Grants (RPGs)      
Research Project Grants (Excluding Small Business RPGs)

 

   
Regular Research Grants (R01)

3,376

1,328,733

57.51%
Small Research Grants (R03)

1

73
0.00
Program Project Grants (P01)

195

380,358
16.46
Cooperative Agreements (U01)

221

203,546
8.81
Area Grants (R15)

21

4,201
0.18
Explorative Developmental Grant (R21)

107

20,232
0.88
Method to Extend Research in Time (R37)

77

30,667
1.33
Subtotal, Research Project Grants (Excluding Small Business RPGs)
3,998
1,967,810
85.17
Small Business Research Project Grants
     
Small Business Technology Transfer (STTR Phase I) (R41)
25
4,212
0.18
Small Business Technology Transfer (STTR Phase II) (R42)
13
5,291
0.23
Small Business Innovation Research (SBIR Phase I) (R43)
90
14,017
0.61
Small Business Innovation Research (SBIR Phase II) (R44)
104
50,220
2.17
Small Business Innovation Research (SBIR) Cooperative Agreements (U44)
---
500
0.02
Subtotal, Small Business Research Project Grants
232
74,240
3.19
Subtotal, Research Project Grants
4,230
2,042,050
88.37
Research Center Grants      
Specialized Centers of Research (SCOR)
52
115,730
5.01
Animal Model and Animal and Biological Material Resource Grants (P40)
---
125
0.01
Sickle Cell Centers (U54)
12
24,314
1.05
Center for AIDS Research (P30)
---
2,815
0.12
Specialized Centers (Cooperative Agreements) (U54)
5
8,186
0.35
National Swine Research and Resource Center (U42)
---
325
0.01
Subtotal, Research Center Grants
69
151,495
6.56
Research Career Programs      
Mentored Research Development Award for Minority Faculty (K01)
45
6,088
0.26
Minority Institution Faculty Mentored Research Scientist Award (K01)
4
588
0.03
Mentored Scientist Development Award in Research Ethics (K01)
3
355
0.02
Independent Scientist Award (K02)
32
3,218
0.14
Research Career Award (K06)
1
34
0.00
Cultural Competence and Health Disparities Academic Award (K07)
14
1,620
0.07
Clinical Investigator Scientist Award (K08)
239
30,429
1.32
Career Enhancement Award for Stem Cell Research (K18)
3
512
0.02
Mentored Patient-Oriented Research Career Development Award (K23)
127
17,086
0.74
Midcareer Investigator Award in Patient-Oriented Research (K24)
32
3,929
0.17
Mentored Quantitative Research Career Development Award (K25)
17
2,206
0.10
Clinical Research Curriculum Award (K30)
---
4,589
0.20
Career Transition Award (K22)
2
364
0.02
Subtotal, Research Career Programs
519
71,018
3.08
Other Research Grants      
Cooperative Clinical Research (U10, R10)
38
26,295
1.14
Minority Biomedical Research Support (S06, S14, R25)
---
2,846
0.12
Other (R09, R13, R18, R24, R25, T15, U09, U24, UH1)
98
16,554
0.72
Subtotal, Other Research Grants
136
45,695
1.98
Total, NHLBI Research Grants
4,954
$2,310,258
100%

NHLBI Total Research Grants by Category

NHLBI Total Research Grants by Category
Text-only with data points

Back to Top

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations: Fiscal Years 1995–2005

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations: Fiscal Years 1995�2005
Text-only with data points are represented in the table below.

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations: Fiscal Years 1995–2005

  Dollars (Thousands)
  Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Research $819,674 $862,027 $935,322 $1,009,152 $1,142,473 $1,356,034 $1,580,751 $1,779,573 $1,920,201 $2,003,769 $2,042,050
  Project                      
  Grants*                      
Research 106,980 106,688 108,665 114,397 119,889 123,803 127,232 128,161 138,941 140,600 151,495
  Centers                      
  Grants                      
Other                      
  Research 55,974 56,692 56,993 66,234 84,219 90,666 88,958 98,460 113,172 112,785 116,713
  Grants†                      
Total $982,628 $1,025,407 $1,100,980 $1,189,783 $1,346,581 $1,570,503 $1,796,941 $2,006,194 $2,172,314 $2,257,154 $2,310,258
* Includes R01, R03, U01, P01, R37, R41, R43, and R44; R29 in 1994–2002; R55 in 1995–1996; R15 and R42 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.
† Includes Research Career Programs; excludes General Research Support Grants.
‡ Includes Program Evaluation and IMPAC II Assessment of $4,435,000.

Back to Top

NHLBI Competing Research Project Grant Applications*: Fiscal Years 1995–2005

Total Cost Dollars Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*: Fiscal Years 1995-2005
Text-only with data points are represented in the table below.

NHLBI Competing Research Project Grant Applications: Fiscal Years 1995–2005

Total Cost Dollars Reviewed and Awarded

Dollars (Millions)
Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Applications Reviewed $710.3 $699.2 $802.1 $687.1 $867.1 $809.8 $851.7 $1,221.7 $1,262.5 $1,277.6 $1,381.0
Awarded 207.5 182.1 240.1 252.4 330.4 418.4 424.3 437.4 463.7 477.3 447.8
* Includes R01, R03, U01, P01, and R37; R29 in 1994–2002; R55 in 1995–1996; R15 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.
† The number for applications reviewed is based on preliminary data.

NHLBI Competing Research Project Grant Applications*: Fiscal Years 1995–2005

Number Reviewed and Awarded

NHLBI Competing Research Project Grant Applications: Fiscal Years 1995-2005
Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded (Dollars in Millions)
  Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Applications Reviewed 2,744 2,605 2,771 2,657 2,704 2,893 2,895 3,064 3,098 3,548 3,865
RPGs Awarded 740 652 821 837 959 1,003 1,033 1,018 1,064 1,034 909
Success Rate (percent) 27.0 25.0 29.6 31.5 35.5 34.7 35.7 33.2 34.3 29.1 23.5
* Includes R01, R03, U01, P01, and R37; R29 in 1994–2002; R55 in 1995–1996; R15 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.
† The number of applications reviewed is based on preliminary data.

Percent of Reviewed Applications Funded (Success Rate)

Percent of Reviewed Applications Funded (Success Rate)
Text-only with data points

Back to Top

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 1995–2005

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 1995-2005
Text-only with data points are represented in the table below.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations: Fiscal Years 1995–2005

  Dollars (Millions)
  Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Investigator-Initiated* $750.7 $804.1 $867.9 $966.6 $1,069.9 $1,241.6 $1,446.2 $1,584.9 $1,681.9 $1,773.4 $1,822.9
Institute-Initiated† 231.9 216.8 233.0 223.2 276.7 328.9 350.7 421.3 490.4 483.8 487.3
Total $982.6 $1,020.9 $1,100.9 $1,189.8 $1,346.6 $1,570.5 $1,796.9 $2,006.2 $2,172.3 $2,257.2 $2,310.2
* Includes R01, R03, U01, P01, R37, R41, R43, and R44; R29 in 1994–2002; R55 in 1995–1996; R15 and R42 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.
† Includes Centers Grants and Cooperative Agreement RFAs.
‡ Excludes Program Evaluation Assessment of $4,435,000.

Back to Top

NHLBI Research Project Grants*: Amount Funded by Type of Award, Fiscal Years 1995–2005

  Dollars (Millions)
  Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Competing                      
New Competing
$111.1 $90.5 $135.8 $147.5 $202.0 $266.4 $280.0 $291.2 $285.5 $290.5 $270.0
Renewal Competing
94.5 90.4 104.0 103.9 127.2 152.0 143.9 143.9 177.2 185.5 176.1
Competing Supplements
1.9 1.2 0.3 1.0 1.2 0.9 0.4 2.3 1.0 1.3 1.7
Subtotal, Competing 207.5 182.1 240.1 252.4 330.4 419.3 424.3 437.4 463.7 477.3 447.8
Noncompeting                      
Subtotal, Noncompeting 588.4 649.9 662.4 721.3 770.6 889.3 1,101.5 1,281.3 1,390.3 1,454.9 1,520.0
Total, Competing and Noncompeting $795.9 $832.0 $902.5 $973.7 $1,101.0 $1,308.6 $1,525.8 $1,718.7 $1,854.0 $1,932.2 $1,967.8
* Includes R01, R03, U01, P01, and R37; R29 in 1994–2002; R55 in 1995–1996; R15 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.

Facility and Administrative (F&A)* Costs of NHLBI Research Project Grants†: Fiscal Years 1995–2005

Dollars (Thousands)
Fiscal Year Direct Cost F&A Cost † Total Cost F&A Cost as a Percent of Direct Cost
1995 $543,502 $252,423 $795,925 46.4%
1996 564,219 267,785 832,004 47.5
1997 611,576 290,915 902,491 47.6
1998 660,009 313,765 973,774 47.5
1999 764,198 336,756‡ 1,100,954 44.1
2000 891,244 417,312 1,308,556 46.8
2001 1,045,144 480,673 1,525,817 46.0
2002 1,182,408 536,324 1,718,732 45.4
2003 1,276,819 577,131 1,853,950 45.2
2004 1,329,106 603,133 1,932,239 45.4
2005 1,355,803 612,007 1,967,810 45.1
* Previously called Indirect Cost.
† Includes R01, R03, U01, P01, and R37; R29 in 1994–2002; R55 in 1995–1996; R15 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.
‡ Excludes Program Evaluation Assessment of $1,216,000.

NHLBI Research Project Grants*: Average Costs, Fiscal Years 1995–2005

NHLBI Research Project Grants: Average Costs, Fiscal Years 1995-2005
Text-only with data points are represented in the table below.

NHLBI Research Project Grants*: Average Costs, Fiscal Years 1995–2005

  Dollars (Thousands)
  Fiscal Year
  1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Noncompeting $312.8 $317.5 $323.0 $322.6 $323.4 $346.6 $390.7 $418.8 $444.4 $458.7 $490.6
Competing 280.4 279.3 292.5 301.6 344.5 418.0 410.8 409.1 406.7 419.7 459.9
Total $303.7 $308.3 $314.2 $316.9 $329.4 $366.6 $396.1 $416.2 $433.8 $447.9 $484.8
* Includes R01, R03, U01, P01, R37, R41, R43, and R44; R29 in 1994–2002; R55 in 1995–1996; R15 and R42 beginning in 1996; R21 beginning in 1997; and R33 beginning in 2001.

Back to Top

NHLBI Cooperative Agreements (U01, U10) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator’s specific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

  Total Obligations Prior to FY 2005 Total FY 2005 Obligations Total Obligations to Date
Heart and Vascular Diseases      
AIM HIGH: Niacin Plus Statin To Prevent Vascular Events
$ --- $663,376 $663,376
Atherosclerosis, Plaque, and CVD in Communities
4,099,685 5,145,549 9,245,234
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)
35,553,973 8,304,235 43,858,208
Cardiovascular Heart Study (CHS) Events Follow-up Study
--- 1,007,645 1,007,645
Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)
4,343,389 5,610,035 9,953,424
Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases
2,827,101 596,406 3,423,507
Claudication Exercise vs. Edoluminal Revascularization
--- 1,368,413 1,368,413
Coronary Revascularization in Diabetic Patients
3,663,095 4,669,362 8,332,457
Dynamic Evaluation of Percutaneous Coronary Intervention
4,714,221 741,144 5,455,365
Family Blood Pressure Program
84,838,159 3,655,901 88,494,060
Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN)
7,871,675 1,920,380 9,792,055
Girls Health Enrichment Multisite Studies (GEMS)
15,098,492 2,369,517 17,468,009
Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
25,044,553 4,483,140 29,527,693
Home Automatic External Defibrillator Trial (HAT)
13,263,462 1,800,742 15,064,384
IMMEDIATE Trial: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care
5,170,411 9,513,736 14,684,147
Interaction of Genes and Environment in Shaping Risk Factors for Heart, Lung, Blood, and Sleep Disorders
35,525,298 10,547,590 46,072,888
Multidisciplinary Study of Right Ventricular Dysplasia
6,252,319 1,195,224 7,447,543
NHLBI Clinical Proteomics Program
--- 5,103,660 5,103,660
Partnership Programs To Reduce Cardiovascular Health Disparities
6,468,544 7,202,208 13,670,752
Pediatric Cardiovascular Clinical Research Network
18,598,211 3,992,212 22,590,423
Pharmacogenetics Research Network
33,206,897 6,334,303 39,541,200
Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST)
2,899,312 2,017,478 4,916,790
Primordial Prevention of Overweight in American Indian Children
--- 354,427 354,427
Programs of Excellence in Gene Therapy
61,140,050 10,803,812 71,943,862
Programs of Excellence in Nanotechnology
--- 6,322,873 6,322,873
Programs of Genomic Applications (PGAs) for Heart, Lung, and Blood Diseases
165,782,192 14,858,305 180,640,497
Resuscitation Outcome Improvement Consortium
6,886,109 9,338,606 16,224,715
Stop Atherosclerosis in Native Diabetics Study (SANDS)
6,681,337 2,323,642 9,004,979
Strong Heart Study
46,438,304 5,300,000 51,738,304
Surgical Treatment for Ischemic Heart Failure (STICH)
13,864,647 6,082,190 13,864,647
Trial of Activity for Adolescent Girls (TAAG)
28,202,937 5,102,829 33,305,766
Weight Loss Maintenance (WLM)
8,054,488 3,098,894 11,153,382
Women’s Ischemia Syndrome Evaluation (WISE)
5,617,360 995,753 6,613,113
Subtotal, Heart and Vascular Diseases 652,106,401 152,823,587 804,929,988
Lung Diseases      
Asthma Clinical Research Network (ACRN), Phase II
16,605,558 8,667,026 25,272,584
Centers for Reducing Asthma Disparities
17,269,191 5,135,604 22,404,795
Childhood Asthma Management Program–Continuation Study (CAMP–CS)/Phase 2
3,532,802 2,622,721 6,155,523
Childhood Asthma Research and Education (CARE) Network
31,398,337 5,704,202 37,102,539
Collaborative Program in Bronchopulmonary Dysplasia
26,302,593 5,353,412 31,656,005
COPD Clinical Research Network
13,691,750 8,437,795 22,129,545
Early Antipseudomonal Therapy in Cystic Fibrosis
1,064,237 1,047,381 2,111,618
Idiopathic Pulmonary Fibrosis Clinical Research Network
--- 3,486,226 3,486,226
Pharmacogenetics of Asthma Treatment
10,847,376 3,361,644 14,209,020
Prospective Investigation of Pulmonary Embolism Diagnosis-III (PIOPED III)
--- 2,301,770 2,301,770
Subtotal, Lung Diseases 120,711,844 46,117,781 166,829,625
Blood Diseases and Resources      
Blood and Marrow Transplant Clinical Research Network
23,181,808 6,459,743 29,641,551
Center for Human Cell Therapy
2,837,171 2,352,572 5,179,743
Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS)
3,435,202 2,922,730 6,357,932
Stroke With Transfusions Changing to Hydroxyurea (SWITCH)
--- 3,345,345 3,345,345
Thalassemia (Cooley’s Anemia) Clinical Research Network
11,374,688 2,729,989 14,104,677
Transfusion Medicine/Hemostasis Clinical Research Network
18,386,476 6,221,140 24,607,616
Subtotal, Blood Diseases and Resources 59,215,345 24,031,519 83,236,864
National Center on Sleep Disorders Research      
Apnea Positive Pressure Long-Term Efficacy Study (APPLES)
9,654,688 3,188,172 12,542,181
Sleep Heart Health Study
18,109,357 1,494,336 19,603,693
Subtotal, National Center on Sleep Disorders Research 27,463,366 4,682,508 32,145,874
Total, NHLBI Cooperative Agreements $859,496,956 $227,655,395 $1,087,142,351

Back to Top

Heart and Vascular Diseases Program

AIM HIGH: Niacin Plus Statin To Prevent Vascular Events, Initiated in Fiscal Year 2005

The purpose of this multicenter clinical trial is to determine whether extended-release niacin plus simvastatin is superior to simvastatin alone for preventing or delaying a major CVD event in patients with atherogenic dyslipidemia. Niacin is used to raise HDL (“good”) cholesterol and simvastatin is used to lower LDL (“bad”) cholesterol. Twenty-seven percent of the population will be black.

Obligations

Funding History:
   Fiscal Year 2005—$663,376
Total Funding to Date—$663,376

Current Active Organizations and Grant Numbers

  1. University of Washington
    Seattle, Washington—HL-081616
  2. AXIO Research, LLC
    Seattle, Washington—HL-081649

Atherosclerosis, Plaque, and CVD in Communities, Initiated in Fiscal Year 2004

The purpose of this study is to identify correlates of atherosclerotic plaque characteristics and early changes in the vascular wall in a subset of the biethnic Atherosclerosis Risk in Communities (ARIC) cohort. Investigators will use stored DNA samples to test genomic correlates of plaque characteristics and their ability to predict coronary heart disease and stroke.

Obligations

Funding History:
   Fiscal Year 2005—$5,145,549
   Fiscal Year 2004—$4,099,685
Total Funding to Date—$9,245,234

Current Active Organization and Grant Number
  1. University of Texas Health Science Center
    Houston, Texas
— HL-075572

Back to Top

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D), Initiated in Fiscal Year 2000

The purpose of this trial is to compare alternative treatment strategies for managing type 2 diabetic patients with angiographically proven coronary artery disease and stable angina or ischemia. Revascularization combined with aggressive medical anti-ischemia treatment will be compared to aggressive medical anti-ischemia treatment alone; simultaneously, researchers will determine whether insulin-sensitizing drugs like metformin and the glitazones for controlling blood sugar level offer any survival advantage over drugs that increase insulin level. Twenty percent of the patients are from minority populations.

Obligations

Funding History:
   Fiscal Year 2005—$8,304,235
   Fiscal Years 2000–2004—$35,553,973
Total Funding to Date—$43,854,208

Current Active Organizations and Grant Numbers
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HL-061744
  1. St. Louis University
    St. Louis, Missouri
—HL-061746
  1. Stanford University
    Stanford, California
—HL-061748
  1. University of Vermont
    Burlington, Vermont
—HL-063804

Cardiovascular Heart Study (CHS) Events Follow-Up Study, Initiated in Fiscal Year 2005

The purpose of this project is to enhance the use of data and samples from the CHS during a transition period from the current contract-funded, NHLBI-directed program to one directed by a steering committee of investigators with independently acquired grants. During the follow-up, many of the initial exam components will be repeated and CVD events will be recorded. The data and specimens collected in CHS represent a major national resource for the study of health, aging, and CVD in older adults. Seventeen percent of the participants are from minority populations.

Obligations

Funding History:
   Fiscal Year 2005—$1,007,645
Total Funding to Date—$1,007,645

Current Active Organization and Grant Number
  1. University of Washington
    Seattle, Washington
—HL-080295

Back to Top

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether revascularization of a stenotic renal artery plus medical therapy is associated with improved clinical outcomes compared with medical therapy alone. Thirty percent of the participants will be black.

Obligations

Funding History:Fiscal Year 2005—$5,610,035
   Fiscal Year 2004—$4,343,389
Total Funding to Date—$9,953,424

Current Active Organizations and Grant Numbers
  1. Medical College of Ohio
    Toledo, Ohio
—HL-071556
  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota
—HL-072734
  1. University of Virginia
    Charlottesville, Virginia
—HL-072735
  1. Beth Israel Deaconess Medical Center
    Boston, Massachusetts
—HL-072736
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-072737

Center for Fetal Monkey Gene Transfer for Heart, Lung, and Blood Diseases, Initiated in Fiscal Year 2001

The purpose of this Center is to provide expertise, sources, and resources to NHLBI-supported investigators who wish to evaluate viral and nonviral gene transfer strategies in nonhuman primates.

Obligations

Funding History:
   Fiscal Year 2005—$596,406
   Fiscal Years 2001–2004—$2,827,101
Total Funding to Date—$3,423,507

Current Active Organization and Grant Number
  1. University of California, Davis
    Davis, California
—HL-069748

Claudication Exercise vs. Edoluminal Revascularization, Initiated in Fiscal Year 2005

The purpose of this study is to test the hypothesis that a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with aortoiliac artery obstruction at 6 months. Other objectives are to compare the two treatment groups with a third group, usual care and pharmacotherapy, at 6 months, and to compare maximum walking duration change scores at 18 months, changes in free living daily activity levels, and patient-perceived quality of life among all three groups.

Obligations

Funding History:
   Fiscal Year 2005—$1,368,413
Total Funding to Date—$1,368,413

Current Active Organizations and Grant Numbers
  1. Rhode Island Hospital
    Providence, Rhode Island
—HL-077221
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-081658

Coronary Revascularization in Diabetic Patients, Initiated in Fiscal Year 2004

The purpose of this clinical trial is to compare a multivessel stenting strategy using the Sirolimus-eluting stents with CABG in diabetic patients with multivessel disease. The primary outcome is the difference in mortality rates between the stent group and the CABG group during a 5-year period.

Obligations

Funding History:
   Fiscal Year 2005—$4,669,362
   Fiscal Year 2004—$3,663,095
Total Funding to Date—$8,332,457

Current Active Organization and Grant Number
  1. Mount Sinai School of Medicine
    New York, New York
—HL-071988

Back to Top

Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997

This program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is evaluating patterns of device usage, as well as immediate and follow-up outcomes in patients undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and in designing clinical trials to evaluate competing devices.

Obligations

Funding History:
   Fiscal Year 2005—$741,144
   Fiscal Years 1997–2004—$4,714,221
Total Funding to Date—$5,455,365

Current Active Organization and Grant Number
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HL-033292

Family Blood Pressure Program, Initiated in Fiscal Year 1995

The objectives of this program are to identify major genes associated with high blood pressure and to investigate the interactions between genetic and environmental determinants of hypertension in defined populations, many of which consist of specific minority groups. The study consists of collaborative networks that share technology, data, skills, biological materials, and population resources.

Obligations

Funding History:
   Fiscal Year 2005—$3,655,901
   Fiscal Years 1995–2004—$84,838,159
Total Funding to Date—$88,494,060

Current Active Organizations and Grant Numbers
  1. University of Utah
    Salt Lake City, Utah
—HL-054471
  1. Washington University
    St. Louis, Missouri
—HL-054473
  1. University of Texas Health Science Center
    Houston, Texas
—HL-054481
  1. Staub Pacific Health Foundation Health Research Institute
    Honolulu, Hawaii
—HL-054498
  1. University of Michigan at Ann Arbor
    Ann Arbor, Michigan
—HL-054512

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000

The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists seek to identify and characterize genes that contribute to CVD in this unique and understudied population.

Obligations

Funding History:
   Fiscal Year 2005—$1,920,380
   Fiscal Years 2000–2004—$7,871,675
Total Funding to Date—$9,792,055

Current Active Organizations and Grant Numbers
  1. MedStar Research Institute
    Washington, DC
—HL-064244
  1. Norton Sound Health Corporation
    Nome, Alaska
—HL-082458
  1. Southwest Foundation for Biomedical Research
    San Antonio, Texas
—HL-082490

Girls Health Enrichment Multisite Studies (GEMS), Initiated in Fiscal Year 1999

The objective of this project is to develop and test interventions to prevent obesity by decreasing weight gain during the high-risk transitional period from pre-puberty to puberty in black girls who are at risk for developing obesity. Phase 1 (developmental and pilot studies) was completed in FY 2002. Two sites began Phase 2 trials in FY 2003.

Obligations

Funding History:
   Fiscal Year 2005—$2,369,517
   Fiscal Years 1999–2004—$15,098,492
Total Funding to Date—$17,468,009

Current Active Organizations and Grant Numbers
  1. University of Memphis
    Memphis, Tennessee
—HL-062662
  1. Stanford University
    Stanford, Califorinia
—HL-062663

Heart Failure: A Controlled Trial Investigating Outcomes of Exercise (HF-ACTION), Initiated in Fiscal Year 2002

The purpose of this trial is to determine the long-term safety and effectiveness of exercise training for patients with heart failure. Patients receiving the exercise regimen also will receive standard care and will be compared with patients receiving standard care alone.

Obligations

Funding History:
   Fiscal Year 2005—$4,483,140
   Fiscal Years 2002–2004—$25,044,553
Total Funding to Date—$29,527,693

Current Active Organizations and Grant Numbers
  1. Duke University
    Durham, North Carolina
—HL-063747
  1. Case Western Reserve University Henry Ford Health System
    Detroit, Michigan
—HL-064250
  1. Oregon Health & Science University
    Portland, Oregon
—HL-064257
  1. Washington University
    St. Louis, Missouri
—HL-064264
  1. University of Colorado Health Sciences Center
    Denver, Colorado
—HL-064265
  1. Duke University
    Durham, North Carolina
—HL-066461
  1. Emory University
    Atlanta, Georgia
—HL-066482
  1. Wake Forest University
    Winston-Salem, North Carolina
—HL-066491
  1. Ohio State University
    Columbus, Ohio
—HL-066494
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—HL-066497
  1. Case Western Reserve University
    Cleveland, Ohio
—HL-066501
  1. Boston Medical Center
    Boston, Massachusetts
—HL-068973
  1. University of California, Los Angeles
    Los Angeles, California
—HL-068980

Home Automatic External Defibrillator Trial (HAT), Initiated in Fiscal Year 2002

The purpose of this trial is to compare standard response (call 9–1–1 and give cardiopulmonary resuscitation) to sudden cardiac arrest to standard response augmented with automatic external defibrillator use provided by a spouse or other family member in 7,000 survivors of an anterior wall MI. The primary end point is mortality.

Obligations

Funding History:
   Fiscal Year 2005—$1,800,742
   Fiscal Years 2002–2004—$13,263,642
Total Funding to Date—$15,064,384

Current Active Organization and Grant Number
  1. Seattle Institute for Cardiac Research
    Seattle, Washington
—HL-067972

IMMEDIATE Trial: Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care, Initiated in Fiscal Year 2004

The purpose of this program is to study the effects of early administration of glucose, insulin, and potassium (GIK) in reducing mortality in patients from acute coronary syndrome (ACS). Patients experiencing an ACS (including acute MI and unstable angina pectoris) will be treated with GIK as soon as possible in prehospital emergency medical service settings or immediately upon arrival for those presenting to emergency departments.

Obligations

Funding History:
   Fiscal Year 2005—$9,513,736
   Fiscal Year 2004—$5,170,411
Total Funding to Date—$14,684,147

Current Active Organizations and Grant Numbers
  1. New England Medical Center Hospitals
    Boston, Massachusetts
—HL-077821
  1. New England Medical Center Hospitals
    Boston, Massachusetts
—HL-077822
  1. New England Medical Center Hospitals
    Boston, Massachusetts
—HL-077823
  1. New England Medical Center Hospitals
    Boston, Massachusetts
—HL-077826

Back to Top

Interaction of Genes and Environment in Shaping Risk Factors for Heart, Lung, and Blood Diseases and Sleep Disorders, Initiated in Fiscal Year 2002

The purpose of this study is to identify novel genes that interact with specific environmental exposures to modify risk factors for heart, lung, and blood diseases and sleep disorders. The genetic aspects of response to environmental change and related biological mechanisms will be studied using short-term, focused interventions in families. Subgroups will be identified based on genotypes that are most likely to benefit from targeted environmental changes designed to reduce the development or progression of heart, lung, and blood diseases or sleep disorders.

Obligations

Funding History:
   Fiscal Year 2005—$10,547,590
   Fiscal Years 2002–2004—$35,525,298
Total Funding to Date—$46,072,888

Current Active Organizations and Grant Numbers
  1. Tulane University
    New Orleans, Louisiana
—HL-072507
  1. LSU Pennington Biomedical Research Center
    Baton Rouge, Louisiana
—HL-072510
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-072518
  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota
—HL-072524
  1. University of Maryland Baltimore Professional School
    Baltimore, Maryland
—HL-072525

Multidisciplinary Study of Right Ventricular Dysplasia, Initiated in Fiscal Year 2001

The purpose of this multidisciplinary, multicenter study is to investigate the cardiac, clinical, and genetic aspects of arrhythmogenic right ventricular dysplasia (ARVD). A North American ARVD registry of patients and their families will be established. Researchers seek to identify chromosomal loci and specific genetic mutations associated with this disorder.

Obligations

Funding History:
   Fiscal Year 2005—$1,195,224
   Fiscal Years 2001–2004—$6,252,319
Total Funding to Date—$7,447,543

Current Active Organizations and Grant Numbers
  1. University of Arizona
    Tucson, Arizona
—HL-065594
  1. Baylor College of Medicine
    Houston, Texas
—HL-065652
  1. University of Rochester
    Rochester, New York
—HL-065691

NHLBI Clinical Proteomics Program, Initiated in Fiscal Year 2005

The purpose of this program is to promote systematic, comprehensive, large-scale validation of existing and new candidate protein markers that are appropriate for routine use in the diagnosis and management of heart, lung, and blood diseases and sleep disorders. The Program will facilitate validation of protein panels that may be used to predict disease susceptibility or to assist in differential diagnosis, disease staging, selection of individualized therapies, or monitoring of treatment responses. It will also establish a high-quality education and skills development program to ensure that scientists develop the expertise needed to address the complex, multifaceted challenges in clinical proteomics.

Obligations

Funding History:
   Fiscal Year 2005—$5,103,660
Total Funding to Date—$5,103,660

Current Active Organizations and Grant Numbers
  1. Mayo Clinic
    Rochester, Minnisota
—HL-081331
  1. Vanderbilt University
    Nashville, Tennessee
—HL-081332
  1. University of Colorado, Denver
    Denver, Colorado
—HL-081335
  1. Masschusetts General Hospital
    Boston, Massachusetts
—HL-081341

Partnership Programs To Reduce Cardiovascular Health Disparities, Initiated in Fiscal Year 2004

The objectives of this study are to improve the provider and patient approaches to treatment of hypertension and diabetes, modify physician-related barriers to minority enrollment in clinical trials, improve patient adherence to treatment plans, and build sustainable research programs at minority-serving institutions.

Obligations

Funding History:
   Fiscal Year 2005—$7,202,208
   Fiscal Year 2004—$6,468,544
Total Funding to Date—$13,670,752

Current Active Organizations and Grant Numbers
  1. Bon Secours Hospital Baltimore, Inc.
    Baltimore, Maryland
—HL-079150
  1. University of Maryland Baltimore Professional School
    Baltimore, Maryland
—HL-079151
  1. Queen’s Medical Center
    Honolulu, Hawaii
—HL-079152
  1. Cooper Green Hospital (Birmingham)
    Birmingham, Alabama
—HL-079153
  1. Emory University
    Atlanta, Georgia
—HL-079156
  1. Denver Health and Hospital Authority
    Denver, Colorado
—HL-079160
  1. University of Hawaii at Manoa
    Honolulu, Hawaii
—HL-079163
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—HL-079171
  1. University of Colorado Health Sciences Center
    Denver, Colorado
—HL-079208
  1. Morehouse School of Medicine
    Atlanta, Georgia
—HL-079214
  1. Jackson Hinds Comprehensive Health Center
    Jackson, Mississippi
—HL-079378
  1. University of Mississippi Medical Center
    Jackson, Mississippi
—HL-079458

Back to Top

Pediatric Cardiovascular Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this study is to establish a network to systematically evaluate candidate genes that may influence pharmacologic response to drug treatments for arrhythmia, heart failure, hypertension, and lipid disorders. Investigators seek to identify gene polymorphisms capable of predicting drug toxicity and efficacy. One of the projects has 50 percent minority participation.

Obligations

Funding History:
   Fiscal Year 2005—$6,334,303
   Fiscal Years 2001–2004—$33,206,897
Total Funding to Date—$39,541,200

Current Active Organizations and Grant Numbers
  1. Vanderbilt University
    Nashville, Tennessee
—HL-065962
  1. Children’s Hospital and Research Center at Oakland
    Oakland, California
—HL-069757
  1. Stanford University
    Stanford, California
—GM-061374

Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST), Initiated in Fiscal Year 2003

The purpose of this study is to compare the effects of four diets low in saturated fat and differing in macronutrient composition on weight loss and its maintenance in 800 overweight or obese adults. The diet consists of moderate fat (40 percent energy) or low fat (20 percent energy) with two different protein levels (15 and 25 percent). Approximately 20 percent of the participants will be minority.

Obligations

Funding History:
   Fiscal Year 2005—$2,017,478
   Fiscal Years 2003–2004—$2,899,312
Total Funding to Date—$4,916,790

Current Active Organization and Grant Number
  1. Harvard School of Public Health
    Boston, Massachusetts
—HL-073286

Primordial Prevention of Overweight in American Indian Children, Initiated in Fiscal Year 2005

The purpose of this study is to prevent early childhood overweight in American Indian children. A cohort of children born over an 18-month period will be randomized to either a control or intervention condition. The intervention comprises a community-wide intervention coupled with individualized family counseling to improve nutrition and physical activity in infants and toddlers. A central feature of the project is to develop and test culturally appropriate interventions that can be incorporated into clinical programs of the community health care systems or delivered through public health approaches in Native communities.

Obligations

Funding History:
   Fiscal Year 2005—$354,427
Total Funding to Date—$354,427

Current Active Organization and Grant Number
  1. Kaiser Foundation Research Institutes
    Oakland, California
—HL-081624

Back to Top

Programs of Excellence in Gene Therapy, Initiated in Fiscal Year 2000

The objective of these programs is to create an environment that will enable rapid translation of preclinical studies in cardiovascular, pulmonary, and hematologic diseases into human pilot experiments. In addition, the programs are offering training at the interface between basic science and clinical application. Six national cores provide access to specialized services, such as generating vectors for clinical use, performing morphologically based studies, producing and processing hematopoietic stem cells, and performing primate transplantation studies.

Obligations

Funding History:
   Fiscal Year 2005—$10,803,812
   Fiscal Years 2000–2004—$61,140,050
Total Funding to Date—$71,943,862

Current Active Organizations and Grant Numbers
  1. University of Washington
    Seattle, Washington
—HL-066947
  1. Stanford University
    Stanford, California
—HL-066948
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HL-066949
  1. Weill Medical College of Cornell University
    New York, New York
—HL-066952
  1. Weill Medical College of Cornell University
    New York, New York
—HL-067738

Programs of Excellence in Nanotechnology, Initiated in Fiscal Year 2005

The purpose of this program is to establish multidisciplinary teams to develp nanotechnology and biomolecular engineering tools and methodologies to detect and analyze atherosclerotic plaque formation. The program presents an unique opportunity for research collaboration and skills training by bring bioengineering and nanotechnology solutions into medicine and vice versa.

Obligations

Funding History:
   Fiscal Year 2005—$6,322,873
Total Funding to Date—$6,322,873

Current Active Organization and Grant Number
  1. Emory University
    Atlanta, Georgia
—HL-080711

Programs of Genomic Applications (PGAs) for Heart, Lung, and Blood Diseases, Initiated in Fiscal Year 2000

The goal of this program is to develop information, tools, and resources to link genes to biological function. Specifically, researchers seek to identify human genes relevant to heart, lung, blood, and sleep functions. In addition, the PGAs will establish training programs for NHLBI-supported investigators in the use of genomic information and technologies.

Obligations

Funding History:
   Fiscal Year 2005—$14,858,305
   Fiscal Years 2000–2004—$165,782,192
Total Funding to Date—$180,640,497

Current Active Organizations and Grant Numbers
  1. Medical College of Wisconsin
    Milwaukee, Wisconsin
—HL-066579
  1. University of California, San Francisco
    San Francisco, California
—HL-066600
  1. Jackson Laboratory
    Bar Harbor, Maine
—HL-066611
  1. University of California
    Los Angeles, California
—HL-066621
  1. University of Washington
    Seattle, Washington
—HL-066642
  1. University of California Lawrence Berkeley Laboratory
    Berkeley, California
—HL-066681
  1. University of Washington
    Seattle, Washington
—HL-066682

Resuscitation Outcome Improvement Consortium, Initiated in Fiscal Year 2004

The purpose of this program is to establish a resuscitation research consortium to conduct clinical research in the areas of cardiopulmonary arrest and traumatic injury leading to arrest. The consortium will enable investigators to conduct multiple collaborative trials to expedite the translation of promising scientific and clinical advances to improve resuscitation outcomes.

Obligations

Funding History:
   Fiscal Year 2005—$9,338,606
   Fiscal Year 2004—$6,886,109
Total Funding to Date—$16,224,715

Current Active Organizations and Grant Numbers
  1. University of Washington
    Seattle, Washington
—HL-077863
  1. University of Iowa
    Iowa City, Iowa
—HL-077865
  1. Medical College of Wisconsin
    Milwaukee, Wisconsin
—HL-077866
  1. University of Washington
    Seattle, Washington
—HL-077867
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HL-077871
  1. St. Michael’s Hospital
    Toronto, Ontario
—HL-077872
  1. Oregon Health & Science University
    Portland, Oregon
—HL-077873
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—HL-077881
  1. Ottawa Health Research Institute
    Ottawa, Ontario
—HL-077885
  1. University of Texas Southwestern Medical Center
    Dallas, Texas
—HL-077887
  1. University of California, San Diego
    La Jolla, California
—HL-077908

Back to Top

Stop Atherosclerosis in Native Diabetics Study (SANDS), Initiated in Fiscal Year 2002

This study will address the high incidence of cardiovascular disease in a population with a high prevalence of diabetes, but relatively low levels of LDL cholesterol and blood pressure. It will compare aggressive lowering of LDL cholesterol and blood pressure to the usual care standard.

Obligations

Funding History:
   Fiscal Year 2005—$2,323,642
   Fiscal Years 2002–2004—$6,681,337
Total Funding to Date—$9,004,979

Current Active Organization and Grant Number
  1. MedStar Research Institute
    Washington, DC
—HL-067031

Strong Heart Study, Initiated in Fiscal Year 1988

The objectives of this study are to survey CVD morbidity and mortality rates among three geographically diverse groups of American Indians and to estimate their levels of CVD risk factors. Phases II and III of the cohort study extended surveillance of community mortality and assessed development of CVD and changes in CVD risk factors. In Phase III, investigators added a substudy of asthma and a pilot family study. The purpose of Phase IV is to enlarge the family study to 120 families comprising 3,600 members to investigate genetic and environmental contributors of CVD.

Obligations

Funding History:
   Fiscal Year 2005—$5,300,000
   Fiscal Years 1988–2004—$46,438,304
Total Funding to Date—$51,738,304

Current Active Organizations and Grant Numbers
  1. MedStar Research Institute
    Washington, DC
—HL-041642
  1. Missouri Breaks Research, Inc.
    Timberlake, South Dakota
—HL-041652
  1. University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma
—HL-041654
  1. Southwest Foundation for Biomedical Research
    San Antonio, Texas
—HL-065520
  1. Weill Medical College of Cornell University
    New York, New York
—HL-065521

Surgical Treatment for Ischemic Heart Failure (STICH), Initiated in Fiscal Year 2002

The purpose of this clinical trial is to determine whether CABG plus intensive medical therapy improves long-term survival of patients with heart failure and left ventricular (LV) dysfunction who have coronary artery disease amenable to surgical revascularization, compared to medical therapy alone; and to determine whether CABG plus surgical ventricular restoration to a more normal LV size improves survival free of subsequent hospitalizations of patients with anterior LV dysfunction, compared to CABG alone.

Obligations:

Funding History:
   Fiscal Year 2005—$6,082,190
   Fiscal Years 2002–2004—$13,864,647
Total Funding to Date—$19,946,837

Current Active Organizations and Grant Numbers
  1. Thomas Jefferson University
    Philadelphia, Pennsylvania
—HL-069009
  1. Mayo Clinic
    Rochester, Minnesota
—HL-069010
  1. Duke University
    Durham, North Carolina
—HL-069011
  1. Northwestern University
    Chicago, Illinois
—HL-069012
  1. Duke University
    Durham, North Carolina
—HL-069013
  1. Duke University
    Durham, North Carolina
—HL-069015
  1. University of Southern California
    Los Angeles, California
—HL-072683

Trial of Activity for Adolescent Girls (TAAG), Initiated in Fiscal Year 2000

See Chapter 11. Clinical Trials.

Weight Loss Maintenance (WLM), Initiated in Fiscal Year 2003

The purpose of this multicenter trial is to evaluate the effectiveness of two strategies to maintain weight loss for 2½ years in approximately 800 overweight or obese adults. Individuals who are taking medication for hypertension of dyslipidemia or who are diabetic enter a 6-month weight program. Those who lose at least 9 pounds are randomized into one of three groups: one that provides monthly personal contacts with a trained interventionist, primarily by telephone; one that provides frequent contacts through an interactive Web-based program; or usual care. Forty percent of the participants will be black.

Obligations

Funding History:
   Fiscal Year 2005—$3,098,894
   Fiscal Years 2003–2004—$8,054,488
Total Funding to Date—$11,153,382

Current Active Organizations and Grant Numbers
  1. Center for Health Research
    Portland, Oregon
—HL-068676
  1. Duke Hypertensive Center
    Durham, North Carolina
—HL-068734
  1. Center for Health Research
    Portland, Oregon
—HL-068790
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-068920
  1. LSU Pennington Biomedical Research Center
    Baton Rouge, Louisiana
—HL-068955

Women’s Ischemia Syndrome Evaluation (WISE), Initiated in Fiscal Year 2001

The purpose of this study is to extend the follow-up of WISE patients to determine the incremental long-term prognostic value of novel testing developed in WISE, develop sex-specific incremental outcome models to evaluate the prognostic value of female reproductive variables, and maintain a WISE database and infrastructure to facilitate further investigations into the mechanisms underlying ischemic syndromes in women.

Obligations

Funding History:
   Fiscal Year 2005—$995,753
   Fiscal Years 2001–2004—$5,617,360
Total Funding to Date—$6,613,113

Current Active Organization and Grant Number
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HL-064829
  1. University of Florida
    Gainesville, Florida
—HL-064924

Back to Top

Lung Diseases Program

Asthma Clinical Research Network (ACRN) Phase II, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Centers for Reducing Asthma Disparities, Initiated in Fiscal Year 2002

The purpose of this study is to establish cooperative centers of research to reduce asthma disparities between whites and minorities and economically disadvantaged populations. The mission of the centers, comprising partnerships between minority-servicing medical institutions and research-intensive institutions, is to promote interdisciplinary investigation of factors that contribute to disparities in asthma, accelerate development and evaluation of strategies to promote effective asthma management among minority and economically disadvantaged populations, encourage training and career development for minority clinical research investigators, and improve the effectiveness of NHLBI-supported research-intensive institutions in developing and sustaining culturally appropriate research and demonstration activities on reducing disparities.

Obligations

Funding History:
   Fiscal Year 2005—$5,135,604
   Fiscal Years 2002–2004—$17,269,191
Total Funding to Date—$22,404,795

Current Active Organizations and Grant Numbers
  1. Meharry Medical College
    Nashville, Tennessee
—HL-072431
  1. Howard University
    Washington, DC
—HL-072433
  1. Rhode Island Hospital
    Providence, Rhode Island
—HL-072438
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-072455
  1. Vanderbilt University
    Nashville, Tennessee
—HL-072471
  1. Northwestern University
    Chicago, Illinois
—HL-072478
  1. Hektoen Institute for Medical Research
    Chicago, Illinois
—HL-072496
  1. University of Puerto Rico Medical Sciences
    San Juan, Puerto Rico
—HL-072519

Childhood Asthma Management Program–Continuation Study (CAMP–CS)/Phase 2, Initiated in Fiscal Year 2003

The objectives of this observational study are to follow the original CAMP cohort for 4 more years into early adulthood to determine the effects of long-term (3.5 to 5.5 years) corticosteroid therapy, started at ages 5 to 12, on outcomes of pulmonary function, height, bone density, and clinical course of asthma; 31 percent of the participants are from minority groups.

Obligations

Funding History:
   Fiscal Year 2005—$2,622,721
   Fiscal Years 2003–2004—$3,532,802
Total Funding to Date—$6,155,523

Current Active Organizations and Grant Numbers
  1. Washington University
    St. Louis, Missouri
—HL-075232
  1. Hospital for Sick Children
    Toronto, Ontario
—HL-075407
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-075408
  1. Asthma, Inc.
    Seattle, Washington
—HL-075409
  1. University of California, San Diego
    La Jolla, California
—HL-075415
  1. National Jewish Medical and Research Center
    Denver, Colorado
—HL-075416
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-075417
  1. University of Puerto Rico Medical Sciences
    San Juan, Puerto Rico
—HL-075419
  1. University of New Mexico
    Albuquerque, New Mexico
—HL-075420

Childhood Asthma Research and Education (CARE) Network, Initiated in Fiscal Year 1999

See Chapter 11. Clinical Trials.

Back to Top

Collaborative Program in Bronchopulmonary Dysplasia, Initiated in Fiscal Year 1999

The objectives of this program are to support a multi-institutional collaborative research effort by providing a well-defined model of prematurity and bronchopulmonary dysplasia to investigators, and to study mechanisms of lung pathobiology that underlie development of chronic lung disease of prematurity.

Obligations

Funding History:
   Fiscal Year 2005—$5,353,412
   Fiscal Years 1999–2004—$26,302,593
Total Funding to Date—$31,656,005

Current Active Organizations and Grant Numbers
  1. Southwest Foundation for Biomedical Research
    San Antonio, Texas
—HL-052636
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-052638
  1. University of California, San Francisco
    San Francisco, California
—HL-056061
  1. National Jewish Medical and Research Center
    Denver, Colorado
—HL-056263
  1. Barnes Jewish Hospital
    St. Louis, Missouri
—HL-063387
  1. National Jewish Medical and Research Center
    Denver, Colorado
—HL-063397
  1. University of Texas Southwestern Medical Center
    Dallas, Texas
—HL-063399
  1. University of Rochester
    Rochester, New York
—HL-063400
  1. Children’s Hospital of Philadelphia
    Philadelphia, Pennsylvania
—HL-075900
  1. Children’s Hospital
    Boston, Massachusetts
—HL-075904

COPD Clinical Research Network, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Early Antipseudomonal Therapy in Cystic Fibrosis, Initiated in Fiscal Year 2004

The purpose of this study is to determine a safe, effective, and systematic approach for treating young children (ages 1 to 12 years) with cystic fibrosis who are found to be infected with Pseudomonas aemginosa (Pa). The goal is to intervene with antipseudomonal therapy at the first isolation of Pa to delay or prevent chronic infections that lead to irreversible lung destruction.

Obligations

Funding History:
   Fiscal Year 2005—$1,047,381
   Fiscal Year 2004—$1,064,237
Total Funding to Date—$2,111,618

Current Active Organization and Grant Number
  1. Children’s Hospital and Regional Medical Center
    Seattle, Washington
—HL-080310

Idiopathic Pulmonary Fibrosis Clinical Research Network, Initiated in Fiscal Year 2005

See Chapter 11. Clinical Trials.

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment.

Obligations

Funding History:
   Fiscal Year 2005—$3,361,644
   Fiscal Years 2000–2004—$10,847,376
Total Funding to Date—$14,209,020

Current Active Organization and Grant Number
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-065899

Prospective Investigation of Pulmonary Embolism Diagnosis-III (PIOPED III), Initiated in Fiscal Year 2005

The purpose of this study is to determine the diagnostic accuracy of gadolinium-enhanced magnetic resonance angiography of the pulmonary arteries in combination with magnetic resonance venography of the lower extremities for the detection of acute venous thromboembolic disease.

Obligations

Funding History:
   Fiscal Year 2005—$2,301,770
Total Funding to Date—$2,301,770

Current Active Organizations and Grant Numbers
  1. Massachusetts General Hospital
    Boston, Massachusetts
—HL-077149
  1. University of Michigan
    Ann Arbor, Michigan
—HL-077150
  1. University of Calgary
    Calgary, Alberta
—HL-077151
  1. Emory University
    Atlanta, Georgia
—HL-077153
  1. Washington University
    St. Louis, Missouri
—HL-077154
  1. George Washington University
    Washington, D.C.
—HL-077155
  1. St. Joseph Mercy-Oakland
    Pontiac, Michigan
—HL-077358
  1. New York University
    New York, New York
—HL-081593
  1. St. Joseph Mercy-Oakland
    Pontiac, Michigan
—HL-081594

Back to Top

Blood Diseases and Resources

Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Center for Human Cell Therapy, Initiated in Fiscal Year 2004

The purpose of this Center is to serve as a unique resource to facilitate the development of new cellular therapies for a wide range of human diseases, especially heart, lung, and blood diseases and sleep disorders.

Obligations

Funding History:
   Fiscal Year 2005—$2,352,572
   Fiscal Year 2004—$2,827,171
Total Funding to Date—$5,179,743

Current Active Organization and Grant Number
  1. CBR Institute for Biomedical Research
    Boston, Massachusetts
—HL-074355

Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS), Initiated in Fiscal Year 2003

The purpose of this trial is to test whether a more aggressive transfusion strategy that maintains postoperative Hgb levels above 10 g/dl improves functional outcome in cardiovascular patients who are over age 50 and undergoing surgical hip fracture surgery compared to a more conservative strategy that withholds blood transfusion until the patient develops symptoms of anemia.

Obligations

Funding History:
   Fiscal Year 2005—$2,922,730
   Fiscal Years 2003–2004—$3,435,202
Total Funding to Date—$6,357,932

Current Active Organization and Grant Number
  1. Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey
    Piscataway, New Jersey
—HL-073958
  1. Maryland Medical Research Institute, Inc.
    Baltimore, Maryland
—HL-074815

Genotypic Determinants of Aspirin Response in High Risk Families, Initiated in Fiscal Year 2002

The purpose of this study is to identify genes that may modify aspirin’s effect on platelet function and inflammatory biomarker levels in families at increased risk for premature coronary artery disease.

Obligations

Funding History:
   Fiscal Year 2005—$3,307,112
   Fiscal Years 2002–2004—$8,751,227
Total Funding to Date—$12,058,339

Current Active Organization and Grant Number
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-072518

Back to Top

Stroke With Transfusions Changing to Hydroxyurea, Initiated in Fiscal Year 2005

The purpose of this phase III clinical trial is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia. Additional objectives include comparisons of growth and development, frequency of nonstroke neurological and other sickle-related events, and quality of life. The patient population will be black.

Obligations

Funding History:
   Fiscal Year 2005—$3,345,345
Total Funding to Date—$3,345,345

Current Active Organizations and Grant Numbers
  1. St. Jude Children’s Research Hospital
    Memphis, Tennessee
—HL-077878
  1. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina
—HL-078987

Thalassemia (Cooley’s Anemia) Clinical Research Network

See Chapter 11. Clinical Trials.

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

See Chapter 11. Clinical Trials.

National Center on Sleep Disorders Research

Apnea Positive Pressure Long-Term Efficacy Study (APPLES), Initiated in Fiscal Year 2002

The purpose of this study is to evaluate the effectiveness of continuous positive airway pressure (CPAP) therapy to provide significant, stable, and long-term neurocognitive or other benefits to patients with obstructive sleep apnea (OSA). Investigators will identify specific neurocognitive deficits associated with OSA and determine which ones are reversible and most sensitive to the effects of CPAP therapy.

Obligations

Funding History:
   Fiscal Year 2005—$3,188,172
   Fiscal Years 2002–2004—$9,354,009
Total Funding to Date—$12,542,181

Current Active Organization and Grant Number
  1. Stanford University
    Stanford, California
—HL-068060

Sleep Heart Health Study, Initiated in Fiscal Year 1999

The purpose of this multicenter observational study is to determine the degree to which sleep apnea is an independent or contributing risk factor for the development of cardiovascular or cerebrovascular disease.

Obligations

Funding History:
   Fiscal Year 2005—$1,494,336
   Fiscal Years 1999–2004—$18,109,357
Total Funding to Date—$19,603,693

Current Active Organizations and Grant Numbers
  1. University of California, Davis
    Davis, California
—HL-053916
  1. New York University Medical Center
    New York, New York
—HL-053931
  1. University of Minnesota, Twin Cities
    Minneapolis, Minnesota
—HL-053934
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-053937
  1. University of Arizona
    Tucson, Arizona
—HL-053938
  1. Boston University
    Boston, Massachusetts
—HL-053941
  1. Missouri Breaks Research, Inc.
    Timberlake, South Dakota
—HL-063429
  1. Case Western Reserve University
    Cleveland, Ohio
—HL-063463
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-064360
  1. University of Pittsburgh
    Pittsburgh, Pennsylvania
—HL-077813

Back to Top

NHLBI Research Centers (P50, U54, P30) Programs

Specialized Centers of Research (P50) and Specialized Centers of Clinically Oriented Research (P50) Programs

The NHLBI initiated the Specialized Centers of Research (SCOR) program in 1971 to encourage translational research—converting basic science findings to the clinic—in high priority areas. The SCOR concept emphasizes multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute’s mission. In 2002, the NHLBI revised the SCOR program—primarily on recommendation from the NHLBAC—to place more emphasis on clinical research projects. The newly developed SCCOR program still requires clinical and basic scientists to work together on a unified theme, but now requires at least 50 percent of the projects to be clinical. Listed below is the funding history for the individual SCORs/SCCORs supported by the Institute.

  Obligations (Dollars in Thousands)
Area of Concentration Period of Operation Prior to FY 2005 FY 2005 Total to Date
Heart and Vascular Diseases Program        
Cardiac Dysfunction and Disease (SCCOR)
2005–

$ ---

$16,497 $16,497
Molecular Genetics of Hypertension
1996–

82,634

10,285 92,919
Molecular Medicine and Atherosclerosis
1997–

60,235

8,251 68,486
Pediatric Heart Development and Disease (SCCOR)
2004–

13,245

13,245 26,528
Subtotal, Heart and Vascular Diseases Program  

156,114

48,316 204,430
Lung Diseases Program        
Airway Biology and Pathogenesis of Cystic Fibrosis
1988– 58,758 3,615 62,373
Cellular and Molecular Mechanisms of Asthma
1996– 102,887 15,501 118,388
Pathobiology of Fibrotic Lung Disease
1997– 39,023 5,428 44,451
Pathobiology of Lung Development
1996– 62,672 7,585 70,257
Translational Research in Acute Lung Injury (SCCOR)
2003– 23,326 12,306 35,632
Subtotal, Lung Diseases Program   286,666 44,435 331,101
Blood Diseases and Resources Program        
Hemostatic and Thrombotic Disorders
1996– 169,832 7,594 177,426
Transfusion Biology and Medicine
1996– 62,095 3,267 65,362
Transfusion Biology and Medicine (SCCOR)
2005– --- 4,400 4,400
Translational Human Stem Cell Research
2005– --- 1,509 1,509
Subtotal, Blood Diseases and Resources Program   231,927 16,770 248,697
National Center on Sleep Disorders Research        
Neurobiology of Sleep and Sleep Apnea
1998– 35,102 6,208 41,310
Subtotal, National Center on Sleep Disorders Research   35,102 6,208 41,310
Total, Specialized Centers of Research (P50)   $709,809 $115,729 $825,532

Heart and Vascular Diseases Program

Cardiac Dysfunction and Disease

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions related to dysfunction and disease of the myocardium. The program will enable rapid application of basic science findings to the prevention, diagnosis, and treatment of cardiac disorders, including ischemic and other cardiomyopathies, left ventricular dysfunction, metabolic abnormalities, heart failure, and rhythm disturbances. Because some segments of the population disproportionately suffer from heart disease, research that addresses issues of health disparity will be emphasized.

Obligations

Fiscal Year 2005—$16,497,136

Current Active Organizations and Grant Numbers
  1. Columbia University Health Science Center
    New York, New York
—HL-077096
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—HL-077100
  1. University of Cincinnati
    Cincinnati, Ohio
—HL-077101
  1. Cleveland Clinical Lerner College
    Cleveland, Ohio
—HL-077107
  1. Washington University
    St. Louis, Missouri
—HL-077113

Molecular Genetics of Hypertension

The purpose of this SCOR is to elucidate the etiology and pathogenesis of hypertension and to translate the knowledge into improved diagnosis and management of the disease.

Obligations

Fiscal Year 2005—$10,285,182

Current Active Organizations and Grant Numbers
  1. Medical College of Wisconsin
    Milwaukee, Wisconsin
—HL-054998
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-055000
  1. Boston University Medical Center
    Boston, Massachusetts
—HL-055001
  1. University of Iowa
    Iowa City, Iowa
—HL-055006
  1. Yale University
    New Haven, Connecticut
—HL-055007

Molecular Medicine and Atherosclerosis

The goal of this SCOR is to advance understanding of the etiology and pathobiology of the atherosclerotic lesion at the molecular level through modern methods and approaches of molecular medicine. Some of the subprojects have a large minority patient population.

Obligations

Fiscal Year 2005—$8,251,334

Current Active Organizations and Grant Numbers
  1. Columbia University
    New York, New York
—HL-056984
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-056985
  1. University of California, San Diego
    La Jolla, California
—HL-056989
  1. University of Pennsylvania
    Philadelphia, Pennsylvania
—HL-070128

Pediatric Heart Development and Disease

The purpose of this SCCOR is to foster multidisciplinary collaborations so that basic research advances can be translated rapidly to clinical care for children with heart disease. Research focus ranges from the genetic basis of heart valve disease to clinical trials of novel surgical strategies for congenital heart disease repair and immune modulation in pediatric heart transplantation. Two of the centers will have Clinical Research Skills Development Cores to train fellows and junior faculty in clinical research methods.

Obligations

Fiscal Year 2005—$13,282,825

Fiscal Year 2005—$3,615,257

Lung Diseases Program

Airway Biology and Pathogenesis of Cystic Fibrosis

The goals of this SCOR are to investigate the basic mechanisms underlying cystic fibrosis, develop new hypotheses, and apply innovative strategies for approaching clinical and fundamental issues.

Obligations

Fiscal Year 2005—$3,615,257

Current Active Organizations and Grant Numbers
  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina
—HL-060280
  1. University of Iowa
    Iowa City, Iowa
—HL-061234

Cellular and Molecular Mechanisms of Asthma

The objective of this SCOR is to apply critical science and technology to increase understanding of cellular and molecular mechanisms of asthma, including those mechanisms underlying the biological impact of environmental factors.

Obligations

Fiscal Year 2005—$15,501,156

Current Active Organizations and Grant Numbers
  1. University of New Mexico
    Albuquerque, New Mexico
—HL-056384
  1. University of California, San Francisco
    San Francisco, California
—HL-056385
  1. University of Wisconsin
    Madison, Wisconsin
—HL-056396
  1. University of Chicago
    Chicago, Illinois
—HL-056399
  1. Washington University
    St. Louis, Missouri
—HL-056419
  1. University of Pennsylvania
    Philadelphia, Pennsylvania
—HL-067663
  1. Beth Israel Deaconess Medical Center
    Boston, Massachusetts
—HL-067664
  1. University of Arizona
    Tucson, Arizona
—HL-067672
  1. Stanford University
    Stanford, California
—HL-067674

Pathobiology of Fibrotic Lung Disease

The purpose of this SCOR is to study cellular and molecular mechanisms involved in transition from inflammatory events associated with early fibrotic disease to later processes involving wound healing, repair, and fibrosis.

Obligations

Fiscal Year 2005—$5,427,833

Current Active Organizations and Grant Numbers
  1. University of Michigan at Ann Arbor
    Ann Arbor, Michigan
—HL-056402
  1. University of California, Los Angeles
    Los Angeles, California
—HL-067665
  1. National Jewish Center for Immunology and Respiratory Diseases
    Denver, Colorado
—HL-067671

Pathobiology of Lung Development

The objective of this SCOR is to foster multidisciplinary research enabling basic science findings to be rapidly applied to clinical problems related to lung development. The program focuses on identification of the molecular variables involved in lung development and assessment of the impact of injury during critical periods.

Obligations

Fiscal Year 2005—$7,584,895

Current Active Organizations and Grant Numbers
  1. Children’s Hospital Medical Center
    Cincinnati, Ohio
—HL-056387
  1. Children’s Hospital of Philadelphia
    Philadelphia, Pennsylvania
—HL-056401
  1. University of Colorado Health Sciences Center
    Denver, Colorado
—HL-057144
  1. Children’s Hospital
    Boston, Massachusetts
—HL-067669

Translational Research in Acute Lung Injury

The purpose of this SCCOR is to foster multidisciplinary research to improve the prevention, diagnosis, and treatment of acute lung injury and its more severe form—adult respiratory distress syndrome. This program includes phase II clinical trials and studies of molecular mechanisms of inflammation and coagulation, gene and protein expression, and cell and animal models of lung injury.

Obligations

Fiscal Year 2005—$12,305,723

Current Active Organizations and Grant Numbers
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-073994
  1. University of Washington
    Seattle, Washington
—HL-073996
  1. University of California, San Francisco
    San Francisco, California
—HL-074005
  1. University of Michigan at Ann Arbor
    Ann Arbor, Michigan
—HL-074024

Blood Diseases and Resources Program

Hemostatic and Thrombotic Disorders

The purpose of this SCOR is to investigate pathogenic mechanisms involved in human thrombotic disease and to develop improved methods for its diagnosis and treatment. One of the studies has a large minority patient population.

Obligations

Fiscal Year 2005—$7,543,875

Current Active Organizations and Grant Numbers
  1. Mount Sinai School of Medicine
    New York, New York
—HL-054469
  1. University of Pennsylvania
    Philadelphia, Pennsylvania
—HL-054500
  1. University of Oklahoma
    Oklahoma City, Oklahoma
—HL-054502
  1. Baylor College of Medicine
    Houston, Texas
—HL-065967

Transfusion Biology and Medicine

The purpose of this SCOR is to foster new approaches for improving the availability, efficacy, safety, and quality of blood and blood products for therapeutic uses. One of the centers has a large minority population.

Obligations

Fiscal Year 2005—$3,267,069

Current Active Organizations and Grant Numbers
  1. New York Blood Center
    New York, New York
—HL-054459
  1. University of California, San Francisco
    San Francisco, California
—HL-054476

Transfusion Biology and Medicine

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions to enable rapid application of basic science findings to clinical problems associated with improving the availability, efficacy, safety, and quality of blood and blood products for therapeutic uses.

Obligations

Fiscal Year 2005—$4,400,002

Current Active Organizations and Grant Numbers
  1. Puget Sound Blood Center
    Seattle, Washington
—HL-081015
  1. University of California, San Francisco
    San Francisco, California
—HL-081027

Translational Human Stem Cell Research

The purpose of this SCCOR is to stimulate multi-disciplinary collaboration among basic stem cell biologists, researchers, and clinicians with disease-specific expertise, physicians and surgeons skilled in innovative modes of cell delivery, and investigators experienced in developing and assessing animal models of human diseases to conduct hitherto-unexplored projects such as preclinical studies for cell-based therapy employing human stem cells in animal models. Research findings will ultimately lead to innovative approaches for the prevention, treatment, and cure of disease, and will accelerate the translation of basic scientific discoveries into new therapies.

Obligations

Fiscal Year 2005—$1,509,262

Current Active Organizations and Grant Numbers
  1. University of California, Davis
    Davis, California
—HL-085036

National Center on Sleep Disorders Research

Neurobiology of Sleep and Sleep Apnea

The objective of this SCOR is to integrate molecular, cellular, and genetic approaches to sleep control with clinical investigations on the etiology and pathogenesis of sleep disorders, particularly sleep apnea.

Obligations

Fiscal Year 2005—$6,208,020

Current Active Organizations and Grant Numbers
  1. University of Pennsylvania
    Philadelphia, Pennsylvania
—HL-060287
  1. Brigham and Women’s Hospital
    Boston, Massachusetts
—HL-060292
  1. University of California, Los Angeles
    Los Angeles, California
—HL-060296

Comprehensive Sickle Cell Centers (U54) Program

The Comprehensive Sickle Cell Centers (CSCC) were instituted in FY 1972 to bridge the gap between research and service by combining basic and clinical research, clinical trials and applications training, and community service projects into one program. The patients recruited for the clinical studies are primarily from minority populations.

Obligations

Fiscal Year 2005—$24,313,796

Current Active Organizations and Grant Numbers
  1. Children’s Hospital and Research Center
    Oakland, California
—HL-070583
  1. Thomas Jefferson University
    Philadelphia, Pennsylvania
—HL-070585
  1. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina
—HL-070587
  1. University of Texas Southwestern Medical Center
    Dallas, Texas
—HL-070588
  1. St. Jude Children’s Research Hospital
    Memphis, Tennessee
—HL-070590
  1. University of Southern California
    Los Angeles, California
—HL-070595
  1. Children’s Hospital of Philadelphia
    Philadelphia, Pennsylvania
—HL-070596
  1. Duke University
    Durham, North Carolina
—HL-070769
  1. Boston Medical Center
    Boston, Massachusetts
—HL-070819
  1. Children’s Hospital Research Center
    Cincinnati, Ohio
—HL-070871
  1. Yeshiva University
    New York, New York
—HL-070994

Specialized Centers for Cell-Based Therapies for Heart, Lung, and Blood Diseases (U54) Program

The Specialized Centers for Cell-Based Therapies Program, which includes a Data and Coordinating Center, was initiated in FY 2005 to support preclinical and clinical studies for cell-based therapy for heart, lung, and blood diseases and sleep disorders. A key feature of the program is the ability to conduct preclinical studies in the first year or two of the program, in order to meet the requirements for an Investigational New Drug application prior to initiating clinical studies. Clinical studies are expected to be initiated by the beginning of the third year.

Obligations

Fiscal Year 2005—$6,957,161

Current Active Organizations and Grant Numbers
  1. Baylor College of Medicine
    Houston, Texas
—HL-081007
  1. EMMES Corporation
    Rockville, Maryland
—HL-081021
  1. Johns Hopkins University
    Baltimore, Maryland
—HL-081028
  1. Massachusetts General Hospital
    Boston, Massachusetts
—HL-081030

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

Fiscal Year 2005—$2,829,119

Current Active Organizations and Grant Numbers
  1. New York University School of Medicine
    New York, New York
—AI-27742
  1. University of Washington
    Seattle, Washington
—AI-27757
  1. University of California, San Francisco
    San Francisco, California
—AI-27763
  1. University of Alabama at Birmingham
    Birmingham, Alabama
—AI-27767
  1. University of California, Los Angeles
    Los Angeles, California
—AI-28697
  1. Baylor University
    Houston, Texas
—AI-36211
  1. University of California, San Diego
    La Jolla, California
—AI-36214
  1. Case Western Reserve University
    Cleveland, Ohio
—AI-36219
  1. University of Massachusetts Medical School
    Worcester, Massachusetts
—AI-42845
  1. Miriam Hospital
    Providence, Rhode Island
—AI-42853
  1. Johns Hopkins University
    Baltimore, Maryland
—AI-42855
  1. University of Pennsylvania
    Philadelphia, Pennsylvania
—AI-45008
  1. Emory University
    Atlanta, Georgia
—AI-50409
  1. University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina
—AI-50410
  1. Yeshiva University
    New York, New York
—AI-51519
  1. University of Colorado Health Sciences Center
    Denver, Colorado
—AI-54907
  1. Vanderbilt University
    Nashville, Tennessee
—AI-54999
  1. Harvard Medical School
    Boston, Massachusetts
—AI-60354
  1. Duke University
    Durham, North Carolina
—AI-64518

Back to Top

« Back

Next »

Fact Book Table of Contents

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon